Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-concentration sevoflurane for autism spectrum disorder
ChiCTR2500096191Phase 3Not yet recruiting
- Sponsor
- Guangzhou Women and Children’s Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevoflurane in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Guangzhou Women and Children’s Medical Center. Primary endpoint: Childhood Autism Rating Scale-2 at week 34. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
sevoflurane
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ChiCTR2500096191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096191.